YUP! Too good to be true. YES; Show me a stock that hasn't experienced dilution since May—10 months without any note conversion. Moreover, with a float of approximately 292 million and a market cap of only $426,000, I consider that extraordinarily rare. But wait, there's more. We have numerous catalysts in the pipeline. Firstly, the merger is on the verge of completion. In fact, they wanted to finalize it this Friday, just three days away. Additionally, we've entered into an agreement of intent with an Accredited solution to assume full control of that company. And as if that weren't enough, there's an upcoming spin-off, Pharmazu IPO, which we plan to list on NASDAQ or NYSE/AMEX—with no dilution to Emergent Shareholders. With that go through they will pay the shareholder dividend too.
Reflect on that for a moment. Where else can you find a play like this in the OTC realm with such immense potential? I can't take action for others, but I'm absolutely certain my money will remain parked here until the cows come home.
$EMGE
News 
Market Data 
Discover 
